Kansas House Bill HB2100

Kansas 2025-2026 Regular Session

• Introduced: 1/27/25
• Refer: 1/27/25
• Refer: 3/4/26
• Refer: 3/5/26
• Refer: 3/13/26
• Refer: 3/17/26
• Refer: 4/9/26

Caption

Establishing statewide standards governing the use of HIV post-exposure prophylaxis, permitting a pharmacist to initiate such medication to certain patients, providing civil liability protections to pharmacists who initiate prophylactic therapy to patients for post-exposure to human immunodeficiency virus.

Summary

HB 2100 requires the Kansas State Board of Pharmacy to create a statewide protocol allowing licensed pharmacists to initiate HIV post-exposure prophylaxis (PEP) for individuals believed to have been exposed to HIV. The bill defines key terms, ties eligibility to CDC clinical recommendations, and directs the board to set procedures for recordkeeping, patient education, counseling on timely use, safe administration, contraindications, side effects, and follow-up care with a physician. Under the bill, a pharmacist may provide PEP only within the framework of the statewide protocol, and the patient may not waive the required consultation. The bill also grants pharmacists civil, criminal, and professional liability protection when they act in good faith and with reasonable care in initiating PEP. The Board of Pharmacy must adopt implementing rules and regulations by January 1, 2026, and the measure is made part of the Kansas Pharmacy Act.

Impact

The bill would expand the scope of pharmacy practice in Kansas by authorizing pharmacists to initiate HIV post-exposure prophylaxis under a statewide protocol rather than requiring a physician to start treatment in every case. It would also add new duties for the State Board of Pharmacy to establish clinical and administrative standards, and it would create statutory immunity protections for pharmacists who follow the protocol in good faith. The measure affects pharmacists, patients with potential HIV exposure, and the regulatory framework governing pharmacy practice and professional liability.

Sentiment

No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available materials. Based on the bill text and caption, the measure appears designed as a public-health access bill aimed at speeding treatment after potential HIV exposure while balancing that access with required counseling, documentation, and follow-up safeguards.

Contention

The main policy tension in the bill is between improving rapid access to HIV post-exposure prophylaxis through pharmacists and ensuring patient safety through mandatory consultation, education, and follow-up. Another likely point of concern is the liability shield for pharmacists, which protects those acting in good faith but may raise questions about accountability or the boundaries of pharmacist authority. Because no hearing transcript or vote history is available, no specific legislators, stakeholders, or formal objections can be identified from the record provided.